[8]
Garulli C, Kalogris C, Pietrella L, et al. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling. Cell Signal 2014; 26(2): 352-62.
[9]
Gao J, Muroya R, Huang F, et al. Bone morphogenetic protein induces bone invasion of melanoma by epithelial-mesenchymal transition via the Smad1/5 signaling pathway. Lab Invest 2021; 101(11): 1475-83.
[10]
Carvalho D, Taylor KR, Olaciregui NG, et al. ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Commun Biol 2019; 2: 156.
[11]
Hao J, Lee R, Chang A, et al. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer. PLoS One 2014; 9(6): e90748.
[12]
Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett 2013; 23(11): 3248-52.
[13]
Kerr G, Sheldon H, Chaikuad A, et al. A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis. Angiogenesis 2015; 18(2): 209-17.
[14]
Sanvitale CE, Kerr G, Chaikuad A, et al. A new class of small molecule inhibitor of BMP signaling. PLoS One 2013; 8(4): e62721.
[15]
Tsugawa D, Oya Y, Masuzaki R, et al. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther 2014; 351(3): 549-8.
[16]
Williams E, Bagarova J, Kerr G, et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight 2021; 6(8)
[17]
Hawinkels LJ, de Vinuesa, AG , Paauwe M, Kruithof-de Julio M, Wiercinska E, Pardali E, et al. Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. Clin Cancer Res 2016; 22(1): 96-106.
[18]
Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med 2021; 384(13): 1204-5.
[19]
Strong AL, Spreadborough PJ, Dey D, et al. BMP ligand trap ALK3-Fc attenuates osteogenesis and heterotopic ossification in blast-related lower extremity trauma. Stem Cells Dev 2021; 30(2): 91-105.
[20]
Vanhoutte F, Liang S, Ruddy M, et al. Pharmacokinetics and pharmacodynamics of garetosmab (Anti-Activin A): Results from a first-in-human phase 1 study. J Clin Pharmacol 2020; 60(11): 1424-31.
[21]
Ruiz S, Chandakkar P, Zhao H, et al. Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology. Hum Mol Genet 2017; 26(4): 4786-98.
[22]
Weidner H, Yuan Gao, V , Dibert D, et al. CK2.3, a Mimetic Peptide of the BMP Type I Receptor, Increases Activity in Osteoblasts over BMP2. Int J Mol Sci 2019; 20(23)
[23]
Shimono K, Tung WE, Macolino C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-γ agonists. Nat Med 2011; 17(4): 454-60.
